Pericarditis Market Report 2026

The pericarditis market size has grown strongly in recent years. It will grow from $2.49 billion in 2025 to $2.69 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to limited awareness of pericarditis, reliance on traditional diagnostics, low adoption of advanced imaging, restricted access to specialized cardiac care, predominance of hospital-based treatment.

The pericarditis market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing prevalence of cardiovascular disorders, increasing adoption of digital diagnostics, expansion of outpatient surgical centers, rising investment in precision medicine, integration of AI in cardiac care. Major trends in the forecast period include personalized pericarditis treatment approaches, minimally invasive surgical techniques, early diagnostic innovations, integration of wearable cardiac monitoring, expansion of outpatient cardiac care services.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the pericarditis market in the future. Cardiovascular diseases refer to conditions that affect the heart or blood vessels, often linked to the buildup of fatty deposits inside the arteries and an increased risk of blood clotting. If left untreated, pericarditis can lead to various cardiovascular diseases or even death in extreme cases. As such, the rising rates of cardiovascular diseases are fueling the growth of the pericarditis market. For example, in January 2024, the American Heart Association, a U.S.-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, a 4% rise from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the pericarditis devices market.

The growth of the pericarditis market is expected to be driven by increased healthcare spending. Healthcare spending refers to the total financial resources allocated to various healthcare services and activities within a specific region, country, or healthcare system. Higher healthcare spending fosters an environment that supports the comprehensive management of pericarditis, including research, diagnosis, treatment, and patient education, ultimately benefiting individuals with this condition. For instance, in May 2023, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to a growth of 0.9% in 2022. The UK’s healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. As a result, increased healthcare spending is expected to drive the growth of the pericarditis market.

Major companies operating in the pediatric market are focused on developing next-generation monoclonal antibodies to improve treatment options, enhance therapeutic outcomes, and minimize side effects for children with various medical conditions. These next-generation monoclonal antibodies are engineered to provide better efficacy, specificity, and safety when targeting diseases. For example, in January 2024, Coherus BioSciences, a U.S.-based biotechnology company, launched LOQTORZITM. LOQTORZI is used in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It can also be used as a monotherapy for patients with recurrent, unresectable, or metastatic NPC who have progressed after platinum-containing chemotherapy, regardless of PD-L1 status.

Major companies operating in the pericarditis market are Pfizer Inc., AstraZeneca plc, Merck & Co. Inc., Novartis International AG, Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd., Zydus Cadila Healthcare Ltd., Sun Pharmaceutical Ltd., Kiniksa Pharmaceuticals Ltd., Regeneron Pharmaceuticals Inc., Amgen Inc., Merck KGaA, Hikma Pharmaceuticals plc, AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Roche Holding AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc.

North America was the largest region in the pericarditis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the pericarditis market report during the forecast period. The regions covered in the pericarditis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pericarditis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pericarditis market by affecting the import and cost of advanced medical devices and diagnostic equipment used for treatment and monitoring. Segments such as echocardiogram, ct, and surgical treatment are most impacted, particularly in regions dependent on imports like Asia-Pacific and Europe. The tariffs have increased production and procurement costs, potentially slowing adoption in hospitals and clinics. However, this has also encouraged local manufacturing and innovation in cost-effective diagnostic solutions, creating some positive opportunities for domestic players.

The pericarditis market research report is one of a series of new reports that provides pericarditis market statistics, including pericarditis industry global market size, regional shares, competitors with a pericarditis market share, detailed pericarditis market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis industry. This pericarditis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pericarditis is the inflammation and irritation of the pericardium, the thin, saclike tissue surrounding the heart. The most common symptom is chest pain, which occurs when the layers of the sac rub against the heart and become inflamed.

The main types of pericarditis include acute, chronic, and recurrent pericarditis. Acute pericarditis is a painful inflammation that develops suddenly in the pericardium surrounding the heart. Pericarditis can be diagnosed and treated using various methods, including electrocardiogram (ECG), echocardiogram, computerized tomography (CT), x-ray, medication, and, in some cases, surgical treatment. The treatment of pericarditis is used in a variety of settings, such as hospitals and clinics, medical institutions, ambulatory surgical centers, and research organizations.

The pericarditis market consists of sales of bacterial pericarditis, viral pericarditis, constrictive pericarditis, and subacute pericarditis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The pericarditis market is segmented into bacterial pericarditis, viral pericarditis, constrictive pericarditis and other pericarditis.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.